Introduction of hepatocellular carcinoma {#mjy086s1}
========================================

Liver cancer is the second most lethal cancer worldwide with \~700000 annual deaths globally in recent years ([@mjy086C82]). This accounts for nearly 70% of cancer deaths in developing countries: western and central Africa, east and south-east Asia ([@mjy086C16]). As the most common primary malignancy of the liver, hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide in men, and seventh among women ([@mjy086C63]). Because of the lack of symptoms in the early stages and the rapid growth rate of tumors, most cases of HCC are diagnosed at an advanced stage. The 5-year survival rate for HCC individuals is \<5% ([@mjy086C62]).

There are a number of etiological risk factors for liver cancer, including Hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus (HDV) ([@mjy086C19]). Also, AFB1 exposure has been shown to be highly related to the increasing incidences of liver cancer ([@mjy086C43]). Chronic HBV infection combined with dietary exposure toxin in the high-risk regions, such as central Africa and southeast Asia, is the main reason for the geographic distribution of much higher incidences of HCC. Interestingly, these two risk factors (high AFB1 exposure and/or HBV infection) are also highly associated with the high incidence of a missense mutation of TP53 in HCC patients ([@mjy086C26]; [@mjy086C87]). This mutation is a single base substitution at the third base of codon 249 (AGG to AGT), resulting in the amino acid substitution of serine for arginine (p53-R249S). More interestingly, p53-R249S is the main hotspot mutant identified in overall 30% of HCCs that contain p53 mutations, and in \>96% of HCCs in the high-risk regions ([@mjy086C33]; [@mjy086C77]; [@mjy086C36]; [@mjy086C70]). These epidemiological results suggest that p53-R249S must play an important role in the development, progression and metastasis of HCCs with positive HBV infection and AFB1 exposure, which will be further described below.

Can p53-R249S be a biomarker for HCC? {#mjy086s2}
=====================================

Although HCC surveillance programs have been implemented in specific high-risk populations, early diagnosis of HCC is still a challenging task due to the low sensitivity of current screening methods ([@mjy086C9]). For instance, serum α-fetoprotein (AFP) is the most widely used biomarker in the screening of liver cancer, but its sensitivity is 40%--60% for all stages with the sensitivity for early liver cancer being 40%--50% ([@mjy086C83]; [@mjy086C64]). Therefore, there is an urgent need for more sensitive biomarkers specific for the early diagnosis of HCC.

Like other cancers, HCC also harbors some drastic alterations in the human genome ([@mjy086C40]; [@mjy086C84]; [@mjy086C68]). The identification of DNA modifications in HCC, including mutation and methylation, could be utilized for diagnosis of liver cancers. As mentioned above, one of the highly representative alterations in HCC is the mutation of the tumor suppressor gene TP53 at codon 249 ([@mjy086C24]). In the high incidence areas of HBV infection and AFB1 exposure, the TP53 mutation occurred in \>50% of the cases, among whom there is a high proportion of HCC patients with p53-R249S ([@mjy086C79]). This mutation accounts for 26% of the TP53 mutations described in liver cancer, but is surprisingly rare (\<2%) in other types of human cancers ([@mjy086C80]).

Epidemiological studies have shown that p53-R249S is by far the predominant mutation in the areas of high HCC incidence, such as Egypt, Brazilian, Gambia, Mexico, Nigeria, Senegal, Turkey, Thailand, Southern India, as well as Guangxi and Qidong from China ([@mjy086C11]; [@mjy086C76]; [@mjy086C46]; [@mjy086C78]; [@mjy086C34]; [@mjy086C49]; [@mjy086C31]; [@mjy086C37]; [@mjy086C66]; [@mjy086C67]; [@mjy086C69]). It has been shown that aflatoxin metabolites can induce this mutation *in vitro* and *in vivo* ([@mjy086C28]; [@mjy086C59]). It has also been suggested that p53-R249S might promote carcinogenesis in liver ([@mjy086C79]), but not in other tissues. This raises the possibility of using p53-R249S as a biomarker for diagnosis of HCC in the above high-risk areas. Earlier studies using patients' cancer tissues and blood samples showed that free plasma DNA often contains mutated DNA originated from the tumor lesions ([@mjy086C3]). Thus, it has been attempted to examine plasma DNA for p53-R249S mutation from HCC patients. In the Gambian study, the incidence of p53-R249S mutation in plasma DNA increased with the severity of liver diseases, and this supports the idea that p53-R249S is selected during hepatocarcinogenesis associated with AFB1 exposure ([@mjy086C80]). This study also showed that the p53-R249S mutation could be detected in the plasma DNA of 38% of the patients with liver cancer ([@mjy086C80]). Another study detected plasma R249S-mutated DNA prior to HCC diagnosis in a small number of HCC patients from Qidong, a high-incidence area in China ([@mjy086C38]). In addition, quantitative studies demonstrated a strong correlation between the high copy number of R249S mutation in plasma and HCC in Gambian patients, as there were \>2500 copies of R249S/ml in plasma for \~50% of these HCC patients ([@mjy086C56]). It was also found that HCC is closely correlated with the R249S-containing plasma DNA level with \>10000 copies/ml ([@mjy086C56]). Taken together, these studies suggest that p53-R249S mutation detected in plasma DNA could serve as one biomarker for HBV- and AFB1-associated HCC that harbor this p53 mutant.

Why is p53-R249S solely selected in HCC? {#mjy086s3}
========================================

It has been puzzling why HBV infection and AFB1 exposure specially select the p53-R249S mutation. One possibility would be that AFB1 might selectively target the codon 249 of TP53. AFB1 is a toxin produced by fungi called Aspergillus flavus that grows on improperly stored grain, and metabolized by cytochrome P450 in the liver. It generally causes DNA damage by forming covalent and promutagenic DNA adducts. Specifically, AFB1 metabolites could cause the G→T transversion at the codon 249 of TP53, leading to transfer from AGG to AGT in 50% (Africa) to 90% (Qidong of China) of HCC patients in highly exposed AFB1 region ([@mjy086C8]; [@mjy086C33]; [@mjy086C1]; [@mjy086C72]), which was not detected in other hotspot mutation regions of TP53. Supporting this is an *in vitro* study showing that the context of AGG sequence is a favorable adductive site for AFB1 metabolites ([@mjy086C6]). Hence, this specificity suggests that p53-R249S might have a selective advantage in the development of liver cancer. Then, how is this mutation highly associated with HBV infection in HCC?

It is possible that p53-R249S might also be picked up via a biological selection in HBV-associated HCC. Previous studies suggested that HBV-encoded x protein (HBx) might promote HCC proliferation and growth by interplaying with p53-R249S ([@mjy086C25]; [@mjy086C42]), as silencing either p53-R249S or HBx in HCC cells that harbor both of the proteins retarded cell proliferation and growth. Also, HBx could form a complex with p53-R249S. These results suggest that HBx might execute its oncogenic function by specifically binding to this p53 mutant. However, HBx can also promote cell cycle progression and HCC growth by suppressing and interacting with other negative growth regulators, such as wild-type p53. Thus, the specificity for selecting p53-R249S mutation in HBV-infected HCC could not be interpreted by the interaction of HBx with this p53 mutant.

Another explanation is that HBV infection might endorse the formation of AFB1-induced 249 codon mutation. Chronic inflammation caused by viral replication and infection, such as HBV infection, can lead to oxidative stress in hepatocytes. This might be related to the mutation load of TP53's codon 249 in hepatocytes ([@mjy086C35]). Also, since the expression of CYP 450 enzyme that metabolizes and activates AFB1 is elevated in HBV surface antigen (HBsAg) transgenic mice ([@mjy086C45]), the mutagenic ability of this chemical carcinogen would be more drastically potentiated by HBV infection. Consistent with this conjecture is that the concentration of AFB1 adducts in children and adolescents infected with chronic HBV in Gambia is greater than that of those without this infection ([@mjy086C41]). Moreover, HBV may boost the mutation rate through indirect mechanisms, such as by inducing chronic inflammation, thereby increasing the transformation rate of hepatocytes and the risk of obtaining mutations, such as TP53-R249S ([@mjy086C24]). Although all of these possibilities discussed above seem reasonable, the evidence supporting these speculations is indirect, descriptive, and less convincing. Thus, it still remains mysterious about why HBV infection and AFB1 exposure solely select p53-R249S, rather than other hotspot mutations of p53, in HCC.

Does p53-R249S possess gain-of-function activity in HCC? {#mjy086s4}
========================================================

Similar to other hotspot p53 mutants, p53-R249S displays both loss of function (LOF) and dominant negative (DN) effects crucial for HCC cell proliferation ([@mjy086C22]; [@mjy086C52]). However, unlike R175, R273 and R248 that clearly display their gain-of-function (GOF) in each of their knockin mouse models ([@mjy086C75]; [@mjy086C29]; [@mjy086C65]), genetic knockin of mouse R246S (equivalent to human R249S) only showed LOF and DN effects on tumor development in mice ([@mjy086C51]; [@mjy086C52]). In the R246S knockin study, TP53^R246S/wt^, TP53^−/−^, and TP53^R249S/R249S^ mice showed similar survival rates, and homozygous mutations of p53 at this amino acid, unlike R172H, did not promote further tumorigenesis ([@mjy086C52]). Also, expressing different levels of R246S in the presence of wild-type p53 in mice displayed marked DN effect on acute p53 activation and radiosensitivity in cell-specific and dose-dependent manners ([@mjy086C52]). Clearly, p53-R249S did not show GOF in its knockin mice, although previous studies suggested that p53-R249S might possess a GOF activity in human HCC cells ([@mjy086C50]; [@mjy086C25]). Perhaps, p53-R249S might exert its GOF activity in a context dependent manner ([@mjy086C52]), because the increase of mutant p53 level simply due to Mdm2's absence or DNA damage in tumors is insufficient to convey GOF activity to this mutant p53. Also, the failure of the R249S mutant to inhibit p73 seems to be one of the reasons for its lack of GOF. Finally, p53-R249S does not exhibit GOF properties in other cell types, both in the primary and transformed tissues, and even in the absence of Mdm2. Hence, it remains questionable if p53-R249S possesses a GOF activity key for proliferation, growth, and tumorigenesis of HCC cells. If so, what would be the underlying molecular mechanism, and why its GOF could not be found in p53-R249S knockin mice ([@mjy086C51]; [@mjy086C52])? To address these questions, recent studies offered some new insights as further described below.

SETDB1 methylates p53-R249S and enhances its GOF activity {#mjy086s5}
---------------------------------------------------------

Earlier on, p53-R249S was shown to be regulated by a methyltransferase called SETDB1 (SET domain bifurcated 1, SET domain in the C-terminal region) ([@mjy086C15]). SETDB1 was originally thought to be a protein containing a SET domain ([@mjy086C30]), and its gene is located on human chromosome 1q21.3 with 38.6Kb. It belongs to the family of SET-domain (Su(var)3--9, E(z), Trithorax) protein methyltransferase ([@mjy086C71]). There are two main functional domains: The N-terminal Tudor domain involved in the interaction of proteins and the central MBD domain that mediates the binding of methyl with CpG. It has been shown that SETDB1 can mediate trimethylation of H3K9, leading to gene silencing or transcriptional suppression of some tumor suppressors, such as RASSF1A and p53-binding protein 2 (P53BP2), and thus to play an important role in promoting tumor initiation and progression ([@mjy086C85]; [@mjy086C58]). Although it has been shown that SETDB1 is a possible target for early treatment of Huntington's disease and associated with embryonic development ([@mjy086C61]), it is also often up-regulated in human HCCs through multiple mechanisms, such as at chromosomal (amplification), transcriptional and post-transcriptional levels ([@mjy086C88]). Through a set of bioinformatics, cellular, molecular, and biochemical studies, it has been shown that SETDB1 can regulate p53-R249S stability as well ([@mjy086C15]).

Interestingly, the high copy number and RNA level of the SETDB1 gene were well correlated with the p53-R249S status in HCC tissues. The proportion of p53-R249S mutation increased significantly in HCC specimens that carried more SETDB1 copies or higher RNA levels as examined by exon sequencing, human SNP array 6.0, and RNA expression microarrays. Also, SETDB1 was required for the growth of HCC cells that harbor p53-R249S. R249S, but not wild-type, p53, determined the cell growth sensitivity to SETDB1 knockout, and also rendered HCC cells more dependent on SETDB1. Additionally, SETDB1 tended to form more complexes with p53-R249S than with wild-type p53 as determined by immunoprecipitation. Remarkably, SETDB1 could di-methylate p53-R249S at K370 and stabilize the mutant p53 perhaps by preventing its MDM2-mediated ubiquitination and degradation, whereas the attenuation of SETDB1 activity reduced the level of p53-R249S K370me2 and enhanced MDM2-facilitated proteasomal turnover of this mutant p53 ([@mjy086C15]). This study revealed SETDB1 as an upstream regulator of p53-R249S, whose activity for p53 methylation is likely required for the GOF activity of the mutant p53 in HCC (Figure [1](#mjy086F1){ref-type="fig"}). However, this study does not address how this mutant p53 executes its GOF activity in HCC.

![A schematic showing how p53-R249S may acquire its GOF activity in HCC. Arrows indicate activation, while bars indicate suppression.](mjy086f01){#mjy086F1}

p53-R249S acquires its GOF activity through a wide array of molecules {#mjy086s6}
---------------------------------------------------------------------

That issue has remained unaddressed until a more recent study ([@mjy086C54]) unveiled a unique signaling pathway involving multiple proteins for p53-R249S to execute its GOF activity in HCC cells. Remarkably, all of these proteins have been shown to be involved in tumorigenesis of various cancers either as an oncoprotein, such as CDK4/cyclin D1, Pin1 or c-Myc, or as a tumor suppressor, such as FBW7a ([@mjy086C86]).

CDK4 plays a key role in the G1/S phase of the cell cycle by forming a complex with cyclin D or A family ([@mjy086C39]). The CDK4/cyclin D1 complex is often utilized by tumor cells for their survival and growth advantages, as it is highly expressed in various human cancers ([@mjy086C74]; [@mjy086C60]). One of the important target substrates for this cell cycle-regulated kinase is Rb that is a tumor suppressor and can suppress the progression of the cell cycle by inhibiting the transcriptional activity of E2F or its analogs ([@mjy086C20]). By phosphorylating Rb, CDK4/cyclin D1 inhibits its activity toward E2F, thus boosting the cell cycle progression and proliferation ([@mjy086C47]). In addition, CDK4/cyclin D1 promotes the cell cycle progression and inhibits cell senescence and apoptosis by phosphorylating other proteins as well ([@mjy086C73]). It is through the influence on the cell cycle progression CDK4/cyclin D1 can drive tumorigenic events, including hepatocellular carcinogenesis ([@mjy086C5]). Interestingly, HBx has also been shown to increase CDK4 activity in the development of HBV-related liver cancer ([@mjy086C48]; [@mjy086C18]).

c-Myc is a nuclear transcription factor that is very important for the proliferation and renewal of stem cells as well as the survival of cancer (stem) cells ([@mjy086C7]; [@mjy086C81]; [@mjy086C23]; [@mjy086C44]). One key function of c-Myc is to activate the expression of genes involved in ribosomal biogenesis and protein synthesis ([@mjy086C27]). This oncoprotein is highly expressed in nearly 80% of human cancers ([@mjy086C12]) via multiple mechanisms, including chromosomal translocation, rearrangement, gene amplification, and so on ([@mjy086C10]). It also plays a more global role in regulation of gene transcription crucial for cell proliferation and survival as well as tumorigenesis ([@mjy086C17]; [@mjy086C53]; [@mjy086C55]). Hence, c-Myc is an important oncoprotein essential for the growth and progression of various types of cancer cells including HCC. This oncogenic activity of c-Myc is prevented by FBW7a, a tumor suppressor protein with an intrinsic E3 ubiquitin ligase activity, which can ubiquitinate the former and lead to its degradation ([@mjy086C89]).

Pin1, which is also highly expressed in human cancer, plays a carcinogenic role by converting inactive proteins into active oncoproteins, such as p53 mutants or c-Myc ([@mjy086C90]; [@mjy086C21]; [@mjy086C14]). Pin1 possesses a peptidyl-prolyl cis-trans isomerase activity ([@mjy086C57]), through which it can convert a target protein from its cis conformation to its trans conformation by binding to a phosphorylated Ser-Pro motif ([@mjy086C2]; [@mjy086C4]; [@mjy086C32]). It is through this activity Pin1 could modulate multiple cellular events, including nuclear import, gene regulation, RNA processing, cell proliferation, and differentiation, thus promoting cell proliferation, survival and tumorigenesis. Intriguingly, it has been shown that Pin1 also interplays with HBx and promotes the development of HBV-associated HCC ([@mjy086C13]).

Amazingly, the study by [@mjy086C54] connected all of the aforementioned cancer-related proteins in one single pathway that leads to the 'materialization' of p53-R249S's GOF activity in HCC. Interestingly, mutation of Arg249 to Ser249 in p53 converted this cancer-derived serine residue to a substrate specific for CDK4/cyclin D1, but not for other cell cycle-regulated kinase complexes, during the G1 phase of the cell cycle of HCC cells. Once phosphorylated, p53-R249S became a preferred target with a phosphor-Ser249-Pro250 motif for Pin1, and the latter then bound to p53-R249S at this motif and facilitated its nuclear import. More interestingly, the nuclear-phosphorylated p53-R249S bound to FBW7a and c-Myc and prevented the interaction between the latter two. As a result, p53-R249S inhibited FBW7a ubiquitination of c-Myc, stabilized the latter, and activated its activity, consequently augmenting c-Myc-dependent cell proliferation and survival. Hence, these cellular and biochemical studies unravel that these proteins work in concert to form a unique signaling pathway that equips p53-R249S with a new GOF activity critical for HCC proliferation and growth (Figure [1](#mjy086F1){ref-type="fig"}).

Indeed, this signaling pathway has been confirmed in primary human HCC tissues ([@mjy086C54]). First, higher protein levels of p53-R249S were detected in all of the eight HCC tissues that were HBV positive. Correspondingly, c-Myc, CDK4, and Pin1 levels, as well as p53-R249S phosphorylation, were also relatively higher than that in HCC tissues without the p53-R249S mutation. Notably, the p53-R249S--CDK4--c-Myc complex was also detected in these p53-R249S-harboring HCC tissues. These results demonstrate a novel and unique CDK4/cyclin D1--Pin1--p53-R249S--c-Myc pathway that is crucial for HCC proliferation, survival and carcinogenesis in the HBV-infected environment.

Ending remarks {#mjy086s7}
==============

Since the identification of p53-R249S as the sole hotspot mutation of TP53 in human HCCs that are highly associated with HBV infection and AFB1 exposure in 1991 ([@mjy086C8]; [@mjy086C33]), a great progress has been made to better understand why this mutant is specifically selected in this specific type of HCCs and how it executes its GOF activity in the HCC ([@mjy086C35]; [@mjy086C45]; [@mjy086C6]; [@mjy086C24], [@mjy086C25]; [@mjy086C42], [@mjy086C43]; [@mjy086C15]; [@mjy086C54]). Despite the fact that p53-R249S exhibits its GOF characteristics in a context dependent manner ([@mjy086C52]), from a series of epidemiological, genetic, biochemical, cellular and bioinformatics studies ([@mjy086C8]; [@mjy086C33]; [@mjy086C1]; [@mjy086C11]; [@mjy086C72]; [@mjy086C76]; [@mjy086C3]; [@mjy086C46]; [@mjy086C78]; [@mjy086C34]; [@mjy086C38]; [@mjy086C80]; [@mjy086C49]; [@mjy086C56]; [@mjy086C31]; [@mjy086C37]; [@mjy086C66]; [@mjy086C67]; [@mjy086C69]; [@mjy086C15]; [@mjy086C54]), we have now learned that p53-R249S indeed acquires its GOF activity via specific chemical targeting of R249S by AFB1, biological selection by HBV that creates a microenvironment or molecular environment and reprograms oncogenic signaling pathways leading to unusual posttranslational modifications, such as methylation at K370 by SETDB1 ([@mjy086C15]) and phosphorylation at S249 by CDK4/cyclin D1 ([@mjy086C54]) (Figure [1](#mjy086F1){ref-type="fig"}). However, there are still several outstanding issues that remain to be addressed. First, would K370 methylation and S249 phosphorylation cross talk with each other in implementing the GOF activity of p53-R249S in HCC (Figure [1](#mjy086F1){ref-type="fig"})? Also, would p53-R249S indeed be able to drive HCC development and progression in a more biological setting, such as in an animal model system? Would the CDK4/cyclin D1--Pin1--p53-R249S--c-Myc signaling pathway be more prevalent in a much larger HCC population in China or Africa? Would the GOF activity of p53-R249S play a role in metastasis and drug resistance of late-stage HCCs harboring this mutant p53? If so, this would lead to the last question, i.e. is it possible to co-target them as a combined strategy to develop more effective therapies for HCCs that harbor this p53 mutant, such as co-targeting mutant p53 and CDK4, or even triple-targeting c-Myc, CDK4, and Pin1, and so on? Addressing these issues will certainly further advance our knowledge about the role of p53-R249S in HCC development and provide us with more useful information for developing therapies for this type of cancer, beneficial to human health.
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